PhaseBio Pharmaceuticals Inc (PHAS)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: PHARMACEUTICAL PREPARATIONS

1 GREAT VALLEY PARKWAY MALVERN, PA 19355

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular and cardiopulmonary diseases. The company's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor; pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension; and PB6440, an oral agent for the treatment of resistant hypertension. PhaseBio's proprietary elastin-like polypeptide technology platform enables the development of therapies with potential for less-frequent dosing and improved pharmacokinetics, including pemziviptadil, and drives both internal and partnership drug-development opportunities.

Data as of 2021-07-19 09:50:16 -0400
Market Cap175.025 Million Shares Outstanding47.952 Million Avg 30-day Volume340.737 Thousand
P/E Ratio Dividend Yield EPS
Price/Sales Debt to Equity EBITDA
Price to Book Value0.0 Forward PE0.04 Enterprise Value
Total Cash Current Debt Gross Profit
BETA0.95251 52-week High/Low5.83 / 2.6 Next Earnings Date2021-08-11 Price to Cash FLow (P/CF) -4.0028
Data provided by IEX Cloud
View SEC Filings from PHAS instead.
Q1 2021 All 13F Filers Prior Change Hedge Funds 1 Prior Change
In top 10: 1 1 0.0% 0 (0.0%) 0 (0.0%)
Funds Holding: 62 60 3.33% 18 (1.06%) 17 (0.99%) 5.88%
13F shares: 31.858 Million 15.817 Million 101.41% 17.586 Million 4.249 Million 313.94%
% Ownership 53.8644 59.7295 14.4682 312.83%
New Positions: 10 11 -9.09% 5 4 25.0%
Increased Positions 22 17 29.41% 7 5 40.0%
Closed Positions 7 2 250.0% 4 1 300.0%
Reduced Positions 17 16 6.25% 4 4 0.0%
Total Calls 52.732 Thousand 69.12 Thousand -23.71% 0 15.7 Thousand -100.0%
Total Puts 58.314 Thousand 3 1943700.0% 11 Thousand
PUT/CALL Ratio 1.11 0.0 0.0
1 hedge funds and active managers as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding PHAS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PHAS BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

ARNOLD SUSAN ELIZABETH VP, PRECLINICAL AND CHEM

  • Officer
27,760 2021-07-12 4

HUTSON NANCY J

  • Director
14,000 2021-06-03 1

LOEWY CAROLINE M

  • Director
14,000 2021-06-03 1

THORP CLAY

  • Director
14,000 2021-06-03 3

KLEIN PETER JUSTIN

  • Director
14,000 2021-06-03 1

HARRIGAN EDMUND

  • Director
14,000 2021-06-03 2

VAN DEN BROEK RICHARD

  • Director
14,000 2021-06-03 1

SAPIR ALEX

  • Director
14,000 2021-06-03 1

MOW JONATHAN P CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
126,850 2021-05-20 4

SHARP JOHN P CHIEF FINANCIAL OFFICER

  • Officer
42,724 2021-05-20 4

YORK MICHAEL VP, CORPORATE DEVELOPMENT

  • Officer
7,059 2021-05-20 3

HANSON KRISTOPHER VP, HEAD OF LEGAL

  • Officer
2,087 2021-05-20 3

BURKHARDT GLEN VP, HUMAN RESOURCES

  • Officer
0 2021-05-20 3

LEE JOHN SANG CHIEF MEDICAL OFFICER

  • Officer
0 2021-02-05 1

BALLANCE DAVID JAMES VP, RESEARCH AND SCI. AFFAIRS

  • Officer
8,519 2020-11-20 1

MUKHOPADHYAY BIBHASH

  • Director
0 2019-05-09 0

TUFTS LINDA

  • Director
0 2019-02-27 0

ASTRAZENECA PLC

ZENECA, INC.

  • 10% Owner
3,004,554 2018-10-22 0

HATTERAS VENTURE ADVISORS III, LLC

HATTERAS VENTURES PARTNERS III LP

HATTERAS VENTURE AFFILIATES III LP

HATTERAS VENTURE PARTNERS I, LP

CATALYSTA VENTURES, LLC

VENTURE CAPITAL MULTIPLIER FUND

INGRAM ROBERT ALEXANDER

LEE KENNETH B JR

REED DOUGLAS MD

CRUMPLER JOHN

  • 10% Owner
2,458,049 2018-10-22 0

NEW ENTERPRISE ASSOCIATES 13 LP

NEA PARTNERS 13, LIMITED PARTNERSHIP

NEA 13 GP, LTD

BARRETT M JAMES

BARRIS PETER J

BASKETT FOREST

KERINS PATRICK J

MOTT DAVID M

SANDELL SCOTT D

VISWANATHAN RAVI

  • 10% Owner
6,641,634 2018-10-22 0

RIVERS TYRELL

  • Director
0 2018-10-17 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

ARNOLD SUSAN ELIZABETH - Officer VP, PRECLINICAL AND CHEM

2021-07-14 19:06:33 -0400 2021-07-12 A 4,519 $1.74 a 27,760 direct 3.1073 8.7571 8.7571 6 0.0 1

HUTSON NANCY J - Director

2021-06-04 18:05:23 -0400 2021-06-03 A 14,000 a 14,000 direct

SAPIR ALEX - Director

2021-06-04 18:14:28 -0400 2021-06-03 A 14,000 a 14,000 direct

KLEIN PETER JUSTIN - Director

2021-06-04 18:07:58 -0400 2021-06-03 A 14,000 a 14,000 direct

HARRIGAN EDMUND - Director

2021-06-04 18:08:59 -0400 2021-06-03 A 14,000 a 14,000 direct

THORP CLAY - Director

2021-06-04 18:03:57 -0400 2021-06-03 A 14,000 a 14,000 direct

VAN DEN BROEK RICHARD - Director

2021-06-04 18:17:25 -0400 2021-06-03 A 14,000 a 14,000 direct

LOEWY CAROLINE M - Director

2021-06-04 18:06:37 -0400 2021-06-03 A 14,000 a 14,000 direct

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 22:15:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 21:45:04 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 21:15:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 20:45:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 20:15:04 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 19:45:02 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 19:15:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 18:45:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 18:15:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 17:45:02 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 17:15:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 16:45:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 16:15:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 15:45:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 15:15:03 UTC -1.7514 1.8314 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 14:45:03 UTC -1.7517 1.8317 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 14:15:03 UTC -1.7517 1.8317 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 13:45:03 UTC -1.7517 1.8317 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 13:15:02 UTC -1.7517 1.8317 450000
PHASEBIO PHARMACEUTICALS INC PHAS 2021-07-26 12:45:03 UTC -1.7517 1.8317 450000

Current Active Short Positions

Get more info on our International short position coverage here

Holder Issuer Net Short Position Position Date Origin
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund PHAS -1100.0 shares, $-3806.0 2021-03-31 N-PORT

Short Position History (International Only)

Holder Net Short Position Position Date Origin
Squarepoint Ops LLC PhaseBio Pharmaceuticals Inc 0.5% 2020-02-20 GERMANY

Elevate your investments